Kidney Stones: What the Prevention Evidence Actually Supports

The prevention evidence for recurrent kidney stones is thinner and more conditional than the confident advice around it suggests. The most consistent signal is for fluid: drinking enough to produce at least roughly 2 to 2.5 liters of urine a day lowered recurrence in a landmark randomized trial and anchors both the American College of Physicians (ACP) and American Urological Association (AUA) guidelines, yet the ACP still graded that advice a weak recommendation resting on low-quality evidence. Thiazide diuretics, citrate, and allopurinol each carry randomized support, but mostly within specific metabolic subgroups, and for thiazides a large 2023 trial complicated the picture. A 24-hour urine collection is the test that separates a targeted drug choice from a guess.

What "drink more water" actually rests on

The workhorse study is a 1996 trial by Borghi and colleagues that randomized 199 adults after a first idiopathic calcium stone to either high water intake, aimed at producing more than 2 liters of urine daily, or no specific fluid instruction, then followed them for five years. Recurrence was about 12 percent in the high-intake group versus 27 percent in the control group, and the stones that did form took longer to appear. That single trial does much of the work behind the modern fluid recommendation.

The ACP guideline reflects the limits of that base. Its first recommendation is to increase fluid to reach at least 2 liters of urine per day, graded as a weak recommendation on low-quality evidence. The advice is sensible and low-risk, but it generalizes from mostly first-time calcium stone formers to everyone, which is an extrapolation rather than a settled fact.

Who actually needs a 24-hour urine collection

Here the two guidelines diverge in useful ways. The ACP did not require metabolic testing before starting fluid, a pragmatic stance for a cheap and safe intervention. The AUA guideline goes further for recurrent or high-risk stone formers, recommending a metabolic evaluation built on one or two 24-hour urine collections analyzed at minimum for volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine.

That collection is what converts an empiric guess into a targeted decision. A thiazide makes sense when urine calcium is high, citrate when urinary citrate is low, and allopurinol in a narrow uric-acid phenotype. Without the numbers, drug selection drifts closer to habit than to evidence.

Where the drugs have randomized support, and where they do not

Thiazides

Older randomized trials of thiazide-type agents showed reduced recurrence in recurrent, often hypercalciuric, stone formers, and the ACP graded pharmacologic monotherapy a weak recommendation on moderate-quality evidence. Then the NOSTONE trial, published in the New England Journal of Medicine in 2023, randomized 416 recurrent calcium stone formers to hydrochlorothiazide at 12.5, 25, or 50 mg or to placebo for about three years. Recurrence did not differ substantially across the groups, and there was no clear dose response. One explanation for the gap is selection: NOSTONE enrolled recurrent formers broadly rather than only those with high urine calcium, the group in which thiazides were expected to help most. The result does not erase the earlier evidence, but it argues against assuming a thiazide reliably prevents stones regardless of the metabolic target.

Citrate

Potassium citrate has randomized support in patients with low urinary citrate, where trials showed fewer recurrences, and the AUA offers it to that group. It is also used to raise urinary pH in uric acid and cystine stones. Its case is strongest when a collection documents hypocitraturia and weaker as a blanket measure.

Allopurinol

Allopurinol has the narrowest evidence of the three. A randomized trial found it reduced calcium oxalate recurrence specifically in people with hyperuricosuria and normal urine calcium, and that is exactly the phenotype the AUA targets. Outside that combination, the benefit is not established.

Separating habit from evidence

A few patterns follow. Broad, low-risk habits apply widely and align with both guidelines: hydration first, along with moderating sodium and animal protein and keeping dietary calcium normal rather than low. A separate randomized trial in men with recurrent stones and high urine calcium pointed the same way, finding that a diet with normal calcium but reduced sodium and animal protein produced fewer recurrences than the older low-calcium approach. Drug therapy is different. Its randomized support is subgroup-specific, which is why the AUA anchors it to urine chemistry, and the ACP found that combining agents did not beat monotherapy, so more pills is not more prevention. A broadly recommended step is also not always a strongly evidenced one, as the weak grade on fluid shows.

The honest read is that prevention has one durable habit with modest trial support and several drugs that work in defined metabolic niches, with the boundaries of those niches set by a urine collection rather than by intuition. This article is educational and not medical advice; decisions about testing or medication belong with a qualified clinician who can see the full clinical picture.